Investments
137Portfolio Exits
26Funds
1About The Vertical Group
The Vertical Group is a venture capital firm that is focused on the fields of medical technology and biotechnology. For more than 30 years, the principals of The Vertical Group have been founders, early stage investors, major shareholders, and executives of many of the medical technology industry's companies. The Vertical Group manages private partnerships with a "vertical" range of investments including: early and late venture stage companies; private operating companies involved in buy-out or corporate spin-off transactions; and public companies of all sizes. The Vertical Group is the successor to the venture capital division of F. Eberstadt & Co., and has been an independent firm since 1988.
Want to inform investors similar to The Vertical Group about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing The Vertical Group
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find The Vertical Group in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing The Vertical Group
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned The Vertical Group in 1 CB Insights research brief, most recently on Feb 2, 2021.
Feb 2, 2021
Stealth Startup Funding Surged In 2020Latest The Vertical Group News
Nov 14, 2022
Luminopia , a Cambridge, MA-based prescription digital therapeutics company, raised $5.7M in Seed Extension funding. The round was led by ShangBay Capital, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strateg. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors. The company intends to us the funds for a staged rollout of its lead product for amblyopia to pediatric ophthalmologists starting this month, before expanding to a broader launch in the second half of 2023. Led by CEO Scott Xiao, Luminopia provides treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, Luminopia is developing its lead product to improve vision in children with amblyopia, the leading cause of vision loss among children. The therapeutic is a clinically validated digital therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss among children, and was approved by the U.S. Food and Drug Administration (FDA) through the De Novo pathway in October 2021. Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy. FinSMEs
The Vertical Group Investments
137 Investments
The Vertical Group has made 137 investments. Their latest investment was in Luminopia as part of their Series A on June 6, 2023.
The Vertical Group Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/27/2023 | Series A | Luminopia | $16M | No | 5 | |
10/19/2022 | Seed VC | Luminopia | $5.7M | Yes | Shangbay Capital, Sony Innovation Fund, SSI Strategy, The Vertical Group, and Undisclosed Investors | 2 |
6/20/2022 | Series E | MicroTransponder | $73M | Yes | 7 | |
4/19/2022 | Series B | |||||
12/22/2021 | Seed VC |
Date | 6/27/2023 | 10/19/2022 | 6/20/2022 | 4/19/2022 | 12/22/2021 |
|---|---|---|---|---|---|
Round | Series A | Seed VC | Series E | Series B | Seed VC |
Company | Luminopia | Luminopia | MicroTransponder | ||
Amount | $16M | $5.7M | $73M | ||
New? | No | Yes | Yes | ||
Co-Investors | Shangbay Capital, Sony Innovation Fund, SSI Strategy, The Vertical Group, and Undisclosed Investors | ||||
Sources | 5 | 2 | 7 |
The Vertical Group Portfolio Exits
26 Portfolio Exits
The Vertical Group has 26 portfolio exits. Their latest portfolio exit was Biorez on August 01, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/1/2022 | Acquired | 6 | |||
7/11/2022 | Acquired | 9 | |||
9/15/2020 | IPO | Public | 5 | ||
Date | 8/1/2022 | 7/11/2022 | 9/15/2020 | ||
|---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 6 | 9 | 5 |
The Vertical Group Acquisitions
2 Acquisitions
The Vertical Group acquired 2 companies. Their latest acquisition was Wright Medical Group on December 20, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/20/1999 | Other Venture Capital | $26.61M | Acquired | 3 | ||
12/19/1990 | Growth Equity |
Date | 12/20/1999 | 12/19/1990 |
|---|---|---|
Investment Stage | Other Venture Capital | Growth Equity |
Companies | ||
Valuation | ||
Total Funding | $26.61M | |
Note | Acquired | |
Sources | 3 |
The Vertical Group Fund History
1 Fund History
The Vertical Group has 1 fund, including Vertical Fund I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/31/2005 | Vertical Fund I | Multi-Stage Venture Capital | Closed | $381M | 1 |
Closing Date | 12/31/2005 |
|---|---|
Fund | Vertical Fund I |
Fund Type | Multi-Stage Venture Capital |
Status | Closed |
Amount | $381M |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
